Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Eric Bush

Internal Medicine Gt Barrington, MA Medical Doctor

NPI 1801987151 CMS profile 126850

780 Main St, Ste 1, Gt Barrington, MA 01230

Open in the dashboard

General payments

$13,897

79 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,198 paid to institutions, not to them · program years 2019–2020

Through program year 2023, Eric Bush of Gt Barrington, MA is reported in the CMS Open Payments database as having received $13,897 across 79 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $16,198 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $300 1
2022 General $2,849 5
2021 General $480 1
2020 General $1,795 8
2019 General $8,473 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Bush
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eric Bush were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eric Bush Internal Medicine median Middle half National median
2019 $8,473 $159 $48–$570 $163
2020 $1,795 $119 $33–$402 $114
2021 $480 $135 $37–$521 $132
2022 $2,849 $141 $42–$496 $149
2023 $300 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $13,327 36 payments
  2. GlaxoSmithKline, LLC. $184 15 payments
  3. AstraZeneca Pharmaceuticals LP $75 5 payments
  4. Merck Sharp & Dohme Corporation $42 3 payments
  5. Lilly USA, LLC $39 3 payments
  6. Amgen Inc. $38 2 payments
  7. Sanofi-Aventis U.S. LLC $36 2 payments
  8. Pfizer Inc. $25 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $25 4 payments
  10. E.R. Squibb & Sons, L.L.C. $24 1 payment
  11. Other $83 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,180 14 payments
  2. Food and Beverage $895 57 payments
  3. Travel and Lodging $522 7 payments
  4. Consulting Fee $300 1 payment
Products named General payments · program years 2019–2023
  1. XARELTO $13,327 36 payments
  2. INVOKANA $97 10 payments
  3. ANORO ELLIPTA $55 4 payments
  4. TRELEGY ELLIPTA $53 4 payments
  5. FARXIGA $45 3 payments
  6. ANORO $43 5 payments
  7. JANUVIA $42 3 payments
  8. EMGALITY $39 3 payments
  9. Repatha $38 2 payments
  10. PRALUENT $36 2 payments
  11. Other $317 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 163 drugs

Part D claims

10,605

Median for Internal Medicine: 777

Drug cost

$1,008,388

Median for Internal Medicine: $73,373

Branded share of claims

21.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 183 $167,944
Xarelto Rivaroxaban Brand 128 $146,744
Jardiance Empagliflozin Brand 51 $78,412
Mounjaro Tirzepatide Brand 61 $75,500
Ozempic Semaglutide Brand 61 $62,474
Trulicity Dulaglutide Brand 25 $40,320
Farxiga Dapagliflozin Propanediol Brand 30 $36,657
Januvia Sitagliptin Phosphate Brand 41 $32,903
Ativan Lorazepam Brand 15 $26,994
Repatha Sureclick Evolocumab Brand 49 $26,361

The 10 drugs with the highest cost, of 163 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record